论文部分内容阅读
目的:比较长春瑞滨和紫杉醇分别与铂类联合治疗中晚期子宫内膜癌的近期疗效及毒副反应。方法:33例晚期子宫内膜癌,治疗组(NP方案组)21例,长春瑞滨+顺铂或卡铂化疗,长春瑞滨25mg/m2,静注d1、8;顺铂25mg/m2,静注d1～3,或卡铂(300mg/m2或者AUC4～5)静脉滴注d1。对照组(TP方案组)12例:紫杉醇135～150mg/m2,静注d1;顺铂或卡铂用法同前。结果:全组均完成2周期以上化疗,其中CR4例,PR14例,NC10例,PD5例。有效率(CR+PR)54.54%。NP方案组,CR2例,PR9例,有效率(CR+PR)52.38%;TP方案组,CR2例,PR5例,有效率(CR+PR)58.33%,两组间无统计学差异(P(0.05)。副反应主要为骨髓抑制、白细胞、血小板减少,Ⅲ～Ⅳ度发生率,NP组为71.43%,TP组为75.0%(P(0.05)。结论:长春瑞滨+铂类联合与紫杉醇+铂类联合化疗治疗中晚期子宫内膜癌有相同的疗效且毒副反应可以耐受。
OBJECTIVE: To compare the short-term efficacy and side effects of vinorelbine and paclitaxel with platinum in the treatment of advanced endometrial cancer. Methods: Thirty-one patients with advanced endometrial carcinoma, 21 patients in the treatment group (NP group), vinorelbine + cisplatin or carboplatin, vinorelbine 25 mg / m2, intravenous d1,8; cisplatin 25 mg / m2, Intravenous d1 ~ 3, or carboplatin (300mg / m2 or AUC4 ~ 5) intravenous infusion d1. The control group (TP group) 12 cases: paclitaxel 135 ~ 150mg / m2, intravenous d1; cisplatin or carboplatin usage as before. Results: All the patients were completed more than two cycles of chemotherapy, including CR4 cases, PR14 cases, NC10 cases, PD5 cases. Efficiency (CR + PR) 54.54%. The total effective rate (CR + PR) was 52.38% in NP group, CR2 group and PR9 group. The effective rate (CR + PR) was 58.33% in TP group, CR2 group and PR5 group 0.05) .The adverse reactions were mainly myelosuppression, white blood cells and thrombocytopenia, the incidence of grade Ⅲ ~ Ⅳ was 71.43% in NP group and 75.0% in TP group (P <0.05) .Conclusion: Combination of vinorelbine and platinum with paclitaxel Platinum plus chemotherapy in the treatment of advanced endometrial cancer have the same effect and toxicity can be tolerated.